Uncategorized – Side 8 – European Huntington's Disease Network

Join us at the EHDN 2021 Remote Meeting

Posted on by

Dear Friend of EHDN, On behalf of the members of the Program and Organizing Committee and the Executive Committee of the European Huntington´s Disease Network it is our pleasure to cordially invite you to attend the 3 half-day EHDN Remote Meeting on Thursday – Saturday, September 9-11, 2021. […]

Project: Measuring the Daily Stressors of Young People Affected by Huntington’s Disease

Posted on maj 4, 2021 by

This study is examining what parts of daily life are stressful for young people affected by HD. To understand this, we are asking young people from HD families to share their thoughts on the aspects of their life that are stressful or concerning, such as their family and social relationships, and daily functioning. […]

EHDN statement on the discontinuation of the phase 1b/2a trials PRECISION HD1 and PRECISION HD2

Posted on by

Wave Life Sciences announced on Monday 29th March 2021 that it will discontinue development of two of their three Huntingtin lowering ASO drugs as analysis of the phase 1b/2a trials PRECISION HD1 and PRECISION HD2 showed no evidence of a dose response across the dose levels tested. […]

16th Annual Huntington’s Disease Therapeutics Conference: A Forum for Drug Discovery & Development

Posted on marts 31, 2021 Edited marts 31, 2021 by

CHDI is delighted to announce that the 16th Annual HD Therapeutics Conference will be a fully online, virtual experience to be held April 27-29, 2021. The conference program is currently being crafted and will cover all aspects of drug discovery and development for Huntington’s disease. […]

Huntington’s Australian National Conference 2021

Posted on marts 30, 2021 Edited marts 31, 2021 by

Huntington’s NSW ACT is very pleased to announce it will be hosting the next national HD conference as a series of virtual events from 25 May – 1 June 2021. […]

EHDN statement on the discontinuation of the GENERATION HD1 trial

Posted on by

On Monday 22 March 2021 Roche announced that dosing is being permanently discontinued in the GENERATION HD1 phase III trial evaluating the effect of tominersen, an ASO-based huntingtin lowering drug on the clinical course of HD. Dosing is also being paused on the open label extension study, GEN-EXTEND. This decision is the outcome of a […]